These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 31345399)
1. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study. Mercadante S; Masedu F; Valenti M; Aielli F Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399 [TBL] [Abstract][Full Text] [Related]
2. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study. Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474 [TBL] [Abstract][Full Text] [Related]
3. Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. Mercadante S; Caraceni A; Masedu F; Scipioni T; Aielli F Oncologist; 2020 Feb; 25(2):156-160. PubMed ID: 31862860 [TBL] [Abstract][Full Text] [Related]
4. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial. Lin R; Song B; Li N; Rong B; Bai J; Liu Y; Wang W; Liu A; Luo S; Liu B; Cheng P; Wu Y; Li Y; Yu X; Liu X; Dai X; Li X; Liu D; Wang J; Huang Y BMC Palliat Care; 2024 Sep; 23(1):222. PubMed ID: 39244530 [TBL] [Abstract][Full Text] [Related]
6. Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study. Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1134-1139. PubMed ID: 36808361 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control. Chiang YH; Lien CT; Su WH; Yen TY; Chen YJ; Lai YL; Lim KH; Dai KY; Chung HP; Hung CY; Leu YS BMC Palliat Care; 2024 Jun; 23(1):150. PubMed ID: 38877477 [TBL] [Abstract][Full Text] [Related]
8. Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain. Mercadante S; Adile C; Masedu F; Valenti M; Aielli F J Pain Symptom Manage; 2019 May; 57(5):966-970. PubMed ID: 30822530 [TBL] [Abstract][Full Text] [Related]
9. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. Masel EK; Landthaler R; Gneist M; Watzke HH Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261 [TBL] [Abstract][Full Text] [Related]
10. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. Mercadante S; Ferrera P; Adile C; Casuccio A J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977 [TBL] [Abstract][Full Text] [Related]
11. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890 [TBL] [Abstract][Full Text] [Related]
13. Breakthrough cancer pain: review and calls to action to improve its management. Camps Herrero C; Batista N; Díaz Fernández N; Escobar Álvarez Y; Gonzalo Gómez A; Isla Casado D; Salud A; Terrasa Pons J; Guillem Porta V Clin Transl Oncol; 2020 Aug; 22(8):1216-1226. PubMed ID: 32002739 [TBL] [Abstract][Full Text] [Related]
14. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care. Husic S; Imamovic S; Matic S; Sukalo A Med Arch; 2017 Aug; 71(4):246-250. PubMed ID: 28974843 [TBL] [Abstract][Full Text] [Related]
15. Breakthrough cancer pain in 2020. Løhre ET; Thronæs M; Klepstad P Curr Opin Support Palliat Care; 2020 Jun; 14(2):94-99. PubMed ID: 32332210 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406 [TBL] [Abstract][Full Text] [Related]